Alarelin 5mg

Alarelin 5mg exerts a typical biphasic effect on the HPO axis. In the early stage of administration (1–2 weeks), its high activity enables strong binding to pituitary GnRH receptors, transiently stimulating massive release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a temporary elevation of ovarian steroid hormones. Some patients may experience a "flare-up" phenomenon with transient worsening of dysmenorrhea and pelvic pain.

Following continuous administration, sustained receptor activation triggers downregulation and desensitization, rendering the pituitary refractory. LH and FSH secretion is markedly inhibited, ovarian follicular development is arrested, and estradiol (E2) levels rapidly drop to postmenopausal castration levels (<20 pg/ml). This cuts off estrogen supply to ectopic endometrial lesions, achieving reversible "medical oophorectomy". The process is fully reversible: pituitary-ovarian function gradually recovers within 4–12 weeks after drug withdrawal, with no impact on long-term reproductive capacity.

Beyond core endocrine suppression, the product exerts direct and indirect multiple effects on ectopic lesions.First, it inhibits the proliferation of ectopic endometrial cells, induces apoptosis, downregulates the expression of estrogen receptors (ER) and progesterone receptors (PR) in lesions, and reduces lesion sensitivity to estrogen.

Second, it reduces local angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in lesions, inhibits neovascularization, blocks nutrient supply to lesions, and shrinks the volume of ectopic cysts and nodules.Third, it alleviates local inflammatory responses in lesions, lowers levels of inflammatory factors including prostaglandins and interleukin-6 (IL-6), relieves pelvic adhesions, pain and immune disorders, and improves the core pathological state of EMS.

The large 5mg dosage form offers flexibility for mechanistic research and clinical application.In scientific research, it allows precise preparation of solutions at varying concentrations for gradient administration in in vitro cell experiments (e.g., ectopic endometrial cell culture) and animal models (e.g., rat EMS models), clarifying dose-response relationships.

Clinically, the single dose (150–200 μg/day) can be adjusted according to the patient's condition, body weight and hormone levels. The 5mg dosage supports continuous administration for 25–33 days, matching the standard 3–6 month treatment course, reducing contamination risks from frequent reconstitution and improving medication adherence.

Suitable for mild to moderate patients with prominent pelvic pain, dysmenorrhea, dyspareunia, and no large ovarian chocolate cysts (diameter < 4 cm).The product alone (150 μg/day, subcutaneous/intramuscular injection, initiated on days 1–2 of menstruation) for 3–6 consecutive months results in significant pain relief in 85%–90% of patients, a 50%–80% decrease in serum CA125 levels, and a 30%–60% reduction in ectopic lesion volume.

Combination with it after laparoscopic conservative surgery (cyst enucleation, lesion resection) is a standard EMS treatment regimen.Administration starts 1 week postoperatively for 3–6 months, reducing the 2-year postoperative recurrence rate from 40%–50% to 10%–15%, especially beneficial for stage Ⅲ–Ⅳ severe EMS, patients with residual lesions or severe pelvic adhesions.

For EMS-related infertility, it improves the pelvic microenvironment, relieves inflammatory adhesions, and enhances endometrial receptivity.After 3 months of treatment, the drug is discontinued; natural conception or assisted reproductive technology may be pursued following recovery of ovarian function (1–2 cycles of menstrual resumption). The 6-month pregnancy rate after treatment reaches 45%–55%.

Used for deep infiltrating endometriosis (DIE), ectopic lesions at cesarean section/perineal incisions, intestinal/bladder EMS, etc. It shrinks lesions, relieves pain, reduces surgical difficulty, and serves as palliative therapy for inoperable patients.

Multiple domestic multicenter studies confirm the reliable efficacy of Alarelin 5mg in EMS treatment.One study of 40 EMS patients with infertility showed that after 6 months of treatment, the experimental group (Alarelin + Livial) had a 90% pain relief rate, 85% CA125 negative conversion rate, and 55% 6-month post-withdrawal pregnancy rate.

The control group (Alarelin alone) had an 85% pain relief rate and 45% pregnancy rate, with no significant efficacy difference, though hypoestrogenic symptoms were milder in the experimental group.Another comparative study showed no statistical differences between Alarelin and goserelin in EMS effective rate (90% vs 88%), cyst shrinkage rate (85% vs 82%), or CA125 reduction magnitude, confirming comparable efficacy to imported GnRHa.

As a standardized GnRH agonist, it is widely used in EMS mechanism research.In vitro: treatment of ectopic endometrial cells to observe changes in the expression of HPO axis-related genes (e.g., GnRH-R, ER, PR), inflammatory factors and angiogenic factors, elucidating the mechanisms of estrogen dependence and immune disorders in EMS.In vivo: establishment of rat/mouse EMS models with Alarelin intervention to study regulatory effects on lesion growth, apoptosis, and inflammatory pathways (e.g., NF-κB, TGF-β/Smads).

Used as a positive control drug for in vitro/in vivo efficacy evaluation of novel EMS therapeutics (e.g., GnRH antagonists, selective estrogen receptor modulators).The effects of test compounds versus Alarelin on ectopic cell proliferation, apoptosis and hormone secretion are compared to assess new drug efficacy and advantages. It is also applied in combination therapy research to explore synergistic effects of Alarelin with traditional Chinese medicines and targeted drugs (e.g., anti-VEGF monoclonal antibodies), developing optimized treatment regimens.

Scientific experiments require high-dose, multi-batch dosing; the 5mg dosage form is cost-effective and economical.It enables precise preparation of stock solutions at varying concentrations to meet gradient requirements for cell experiments (nM–μM concentrations) and animal experiments (μg/kg dosages), ensuring stable and reproducible experimental data. It is a core tool drug in reproductive endocrinology and obstetrics and gynecology.